Condition: Systemic Lupus Erythematosus · Active Refractory Rheumatoid Arthritis · Sponsor: Amgen
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research and Innovation Institute | Scottsdale, Arizona, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Vida Research Center | Hialeah, Florida, United States | Terminated |
| Homestead Associates In Research Inc | Homestead, Florida, United States | Terminated |
| Vitaly Clinical Research | Miami, Florida, United States | Terminated |
| Bioresearch Partner Coral Terrace | South Miami, Florida, United States | Recruiting |
| University Medical Center New Orleans | New Orleans, Louisiana, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Northwell Health | Great Neck, New York, United States | Recruiting |
| Westchester Medical Center | Hawthorne, New York, United States | Completed |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
+ 45 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06570798